清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

P81 Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND

作者
Amy S. Paller,Michael J. Cork,Carsten Flohr,Christine Bangert,Stephan Weidinger,John Nesnas,Saleem A. Farooqui,Pinaki Biswas,Melissa Watkins,Herwig Koppensteiner
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:188 (Supplement_4) 被引量:3
标识
DOI:10.1093/bjd/ljad113.109
摘要

Abstract Differences exist in the manifestation and disease course of atopic dermatitis (AD) between adult and adolescent patients. Long-term efficacy of abrocitinib (an oral, once-daily Janus kinase 1-selective inhibitor) was examined in the phase III extension study JADE EXTEND (NCT03422822). This interim post hoc analysis assessed abrocitinib treatment efficacy up to 96 weeks in adolescents and adults with moderate-to-severe AD who enrolled in JADE EXTEND. Eligible adolescents (aged 12 to < 18 years) and adults (≥ 18 years) from the phase III trials JADE MONO-1 (NCT03349060), MONO-2 (NCT03575871), COMPARE (NCT03720470), TEEN (NCT03796676) and DARE (NCT04345367) were enrolled in JADE EXTEND. Patients randomized to abrocitinib (200 mg or 100 mg) in the parent studies received blinded abrocitinib at the same dose in JADE EXTEND; those receiving placebo or dupilumab were randomized to either abrocitinib dose in JADE EXTEND. Patients from JADE DARE received abrocitinib 200 mg in JADE EXTEND. Analyses assessed the proportions of patients achieving an Investigator’s Global Assessment score of clear or almost clear (IGA 0/1); ≥ 75%, ≥ 90% and ≥ 100% improvement from baseline in Eczema Area and Severity Index (EASI-75, EASI-90 and EASI-100, respectively); ≥ 4-point improvement from baseline in Peak Pruritus Numerical Rating Scale score (PP-NRS4; used with permission from Regeneron Pharmaceuticals and Sanofi); PP-NRS score of no or very little itch (PP-NRS 0/1); and ≥ 4-point improvement from baseline in the Patient Oriented Eczema Measure (POEM ≥ 4). The JADE EXTEND data cutoff date was 25 September 2021. This analysis included 357 adolescents and 1309 adults (excluding patients previously randomized to dupilumab). Age at parent study screening visit determined age categorization. Baseline disease severity was higher in adolescents than adults [IGA 4 (severe); 42.3% vs. 36.7%]. At week 96, responder proportions were comparable for adolescents and adults for EASI-75 (abrocitinib 200 mg: 84.4% vs. 85.7%; abrocitinib 100 mg: 81.3% vs. 76.1%), PP-NRS4 (200 mg: 69.4% vs. 69.3%; 100 mg: 60.3% vs. 59.8%) and POEM ≥ 4 (200 mg: 84.4% vs. 88.6%; 100 mg: 79.2% vs. 80.8%), and largely comparable for the stringent endpoints of EASI-90 (200 mg: 62.3% vs. 61.1%; 100 mg: 50.7% vs. 48.1%), EASI-100 (200 mg: 32.5% vs. 21.8%; 100 mg: 18.7% vs. 18.7%), IGA 0/1 (200 mg: 53.2% vs. 55.9%; 100 mg: 49.3% vs. 45.1%) and PP-NRS 0/1 (200 mg: 42.9% vs. 39.5%; 100 mg: 33.3% vs. 32.3%). Long-term efficacy of abrocitinib treatment up to 96 weeks was comparable for adolescents and adults with moderate-to-severe AD, including substantial proportions achieving stringent endpoints of EASI-90, EASI-100, IGA 0/1 or PP-NRS 0/1. Funding sources: Pfizer Inc.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
典雅的醉易完成签到,获得积分10
5秒前
冷酷紫烟完成签到,获得积分10
7秒前
深情的晓槐完成签到,获得积分10
15秒前
Aman完成签到,获得积分10
19秒前
可靠秋蝶完成签到,获得积分10
26秒前
超帅黑夜完成签到,获得积分10
30秒前
CodeCraft的应助被无限幻枫采纳,获得10
33秒前
火星上安柏完成签到,获得积分10
39秒前
45秒前
贪玩的夏真完成签到,获得积分10
51秒前
科研通AI6.4的应助被xingsixs采纳,获得10
51秒前
风中的世平完成签到,获得积分10
59秒前
Aman完成签到,获得积分10
59秒前
懒得起名字完成签到 ,获得积分10
1分钟前
温暖的胜完成签到,获得积分10
1分钟前
无悔完成签到 ,获得积分0
1分钟前
纯真的雁凡完成签到,获得积分10
1分钟前
柔弱的铅笔完成签到,获得积分10
1分钟前
Tracy发布了新的文献求助10
1分钟前
1分钟前
顺利夏云完成签到,获得积分10
1分钟前
xingsixs发布了新的文献求助10
1分钟前
Tracy完成签到,获得积分10
1分钟前
zwlei完成签到,获得积分10
2分钟前
腼腆的雪珊完成签到,获得积分10
2分钟前
热情的衬衫完成签到,获得积分10
2分钟前
xingsixs完成签到,获得积分10
2分钟前
危机的白凡完成签到,获得积分10
2分钟前
徐伟业完成签到 ,获得积分10
2分钟前
RetchieLi完成签到,获得积分10
2分钟前
2分钟前
无限幻枫发布了新的文献求助10
2分钟前
眼睛大的向彤完成签到,获得积分10
2分钟前
俭朴映寒完成签到,获得积分10
2分钟前
汉堡包的应助被bluemoon采纳,获得10
2分钟前
2分钟前
王磊磊0811发布了新的文献求助10
3分钟前
害羞傲安完成签到,获得积分10
3分钟前
外向夜阑完成签到,获得积分10
3分钟前
LINDENG2004完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158937
求助须知:如何正确求助?哪些是违规求助? 9554526
关于积分的说明 21719385
捐赠科研通 7748487
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552013
邀请新用户注册赠送积分活动 2471370